Getting your player ready...
British drug maker GlaxoSmithKline announced Monday that it was setting aside $3.4 billion — wiping out fourth-quarter profits — to pay for U.S. government investigations and product-liability cases over its marketing of the diabetes drug Avandia. The one-time charge is expected to exceed GlaxoSmithKline’s quarterly profits, which are scheduled to be reported Feb. 3.
